However, nearly one in five patients could not tolerate treatment, most often due to adverse breathing events, during one year of follow up. The rate of discontinuation was considerably higher than previously reported in clinical trials, the authors wrote.
In “Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis,” Pierre-Régis Burgel MD, PhD, and colleagues report on their study of 845 patients (292 adolescents, 553 adults) who were treated at 47 cystic fibrosis centers throughout France.
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In 2015 the Food and Drug Administration and the European Medicines Agency approved lumacaftor-ivacaftor in treating patients who have inherited the same defective CFTR gene, known scientifically as the Phe508del mutation, from their parents.
“We felt it was important to obtain real-life post-marketing data in a large population of unselected patients with CF,” said Dr. Burgel, a professor of medicine at Paris Descartes University and a physician at Cochin Hospital, Assistance Publique Hôpitaux de Paris. “Our findings provide a useful complement to randomized clinical trials in which participants were selected based on very strict criteria.”
The study found that patients who took lumacaftor-ivacaftor continuously for 12 months experienced:
- a 3.67 percent increase in their percent predicted FEV1 . FEV1 is an important measure of lung function that measures how much air a person can forcefully exhale in one second after a deep breath. Percent predicted compares how well a patient did on the test to how well the same person with healthy lungs would do.
- A weight increase by approximately 2 to 3 kg (4.5-6.5 lbs.).
- A 35 percent reduction in courses of intravenous antibiotics.
The researchers found that 18.2 percent of participants in the study dropped out. According to the authors, this was “markedly” higher than “pivotal clinical trials,” in which less than 5 percent of patients discontinued the combination therapy. Based on their findings, the authors believe the higher rates in the current study were likely the result of enrolling a higher proportion of patients with severe respiratory disease. However, discontinuation rates in patients with milder disease were also three times higher than in clinical trials, presumably because these patients had less stable disease, the authors said.
Nearly half the patients who discontinued treatment did so because of adverse respiratory events and more than a quarter discontinued treatment due to adverse non-respiratory events, most often digestive problems.
Other study findings:
- Patients who discontinued treatment were more likely to have experienced an exacerbation after IV antibiotics in the year before taking the combination drug.
- Adults were more likely than adolescents to discontinue treatment.
- Adults, but not adolescents, who discontinued therapy were at high risk of rapid FEV1 decline, BMI decrease and multiple respiratory exacerbations.
- The combination therapy was associated with a reduction in frequent (≥ 2) exacerbations per year.
“For patients who are able to continue lumacaftor-ivacaftor, there is clinically meaningful improvement in respiratory disease and nutritional status,” Dr. Burgel said. “However, our study found that the benefits and risks of new therapies cannot be extrapolated to patients who were excluded from clinical trials.”
This study was funded by Vaincre la Mucoviscidose, Société Française de la Mucoviscidose and Legs Pascal Bonnet.
Contact for Media
Pierre-Régis Burgel MD, PhD
Share via Twitter
“Study finds that patients with #cysticfibrosis who take #lumacaftor-ivacaftor (#ORKAMBI®) experience improved lung function, gain weight and experience fewer exacerbations. However, the number of #CF patients who cannot tolerate the drug combination is likely higher than previously reported. @atscommunity @ATSBlueEditor”
About the American Journal of Respiratory and Critical Care Medicine
The AJRCCM is a peer-reviewed journal published by the American Thoracic Society. The Journal takes pride in publishing the most innovative science and the highest quality reviews, practice guidelines and statements in pulmonary, critical care and sleep medicine. With an impact factor of 16.494, it is one of the highest ranked journals in pulmonology. Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.
About the American Thoracic Society
Founded in 1905, the American Thoracic Society is the world’s leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
The ATS will hold its 2020 International Conference, May 15-20, in Philadelphia, Pennsylvania, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.
Original post https://alertarticles.info